Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 465

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 465
---
------------------------:|:--|:----|-----------:|:--|
| Net cash used in operating activities                |     |                (652,051 | ) |     | (7,100,008 | ) |
| Net cash provided by (used in) investing activities  |     |              (2,161,262 | ) |     |     28,210 |   |
| Net cash provided by (used in) financing activities  |     |               5,955,339 |   |     |  4,163,034 |   |
| Net increase (decrease) in cash and cash equivalents |     |               3,142,026 |   |     | (2,908,764 | ) |

Contractual Obligations and Commitments OSR Holdings and its subsidiaries have entered into various contractual arrangements that involve future payments, such as on leases, clinical trials, other R&D activities and minimum purchases of medical devices (for resale). New OSR Holdings’ obligations for those payments in 2024, which vary in time and amount, are currently expected to be approximately KRW 7.55 billion. Those contracts for which the amount payable pursuant to the contract exceeds 5.0% of OSR Holdings revenues are described in the following table.

| Name of Party       |     |        Amounts Due 
 (KRW in thousands) |     | Due Dates |     | Termination date |     | Description and Material terms                                                            |
| Biotoxtech          |     |            800,000 |     | N/A       |     | 12/31/2025       |     | Pre-clinical studies of DRT – 101; payment schedule varies on clinical progress           |
| Microport Neurotech |     |          1,360,000 |     | N/A       |     | 12/31/2025       |     | Distribution agreement; Payment schedule varies on order (60 days after invoice issuance) |

The remaining contractual obligations relate to leases, accounting and related services. Storage, insurance, and other expenses (see Note 25 to the financial statements). Foreign Currency Exchange Risk Our subsidiaries are located outside the U.S., including Korea, Switzerland, and France, and their expenses are generally denominated in the currencies of the jurisdictions in which they conduct operations. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. We experience fluctuations in net loss as